GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » 3-Year Revenue Growth Rate

Paion Ag (Paion Ag) 3-Year Revenue Growth Rate : 56.90% (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag 3-Year Revenue Growth Rate?

Paion Ag's Revenue per Share for the six months ended in Jun. 2023 was $1.03.

During the past 12 months, Paion Ag's average Revenue per Share Growth Rate was -48.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 56.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 38.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Paion Ag was 213.90% per year. The lowest was -88.20% per year. And the median was -2.60% per year.

Competitive Comparison of Paion Ag's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Paion Ag's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paion Ag's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion Ag's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Paion Ag's 3-Year Revenue Growth Rate falls into.


Paion Ag 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Paion Ag  (OTCPK:PAIOF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Paion Ag 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Paion Ag's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Paion Ag (Paion Ag) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
FRA:SPB HAM:GWK3 STU:DWB FRA:BBI HAM:TLG ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124 BOM:532321
Traded in Other Exchanges
PA8:Germany
Address
Heussstrasse 25, Aachen, DEU, 52078
Website
https://www.paion.com
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.